WithdrawnPhase 4ketamine

Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone

Sponsored by Antonios Likourezos

NCT ID
NCT03909594
Start Date
2022-01-01
Est. Completion
2023-12-31

About This Study

The project is meant to evaluate the effect of a combination of medications (Bupivacaine + Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency Department (ED) with hip and/or femur fractures. The goal is to see whether the combination of these two medications will result in greater and longer-lasting pain relief, longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.

Conditions Studied

Pain, Musculoskeletal

Interventions

  • Bupivacaine
  • Ketamine

Eligibility

Age:18 Years - 120 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* 18 years and older
* Presenting with isolated hip or femur fracture confirmed on x-ray.

Exclusion Criteria:

* Polytrauma
* Unstable vitals signs
* Allergy to Bupivacaine or Ketamine
* Inability to give consent
* Altered mental status
* Greater than 100kg
* Known end stage renal disease or hepatic dysfunction
* Received \> 2 doses of Morphine in ER prior to regional nerve block
* Patients with failed nerve block (30 minute onset)

Study Locations (1)

Maimonides Medical Center
Brooklyn, New York, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source